Status | Study |
Withdrawn |
Study Name: Botanical Therapy in Treating Mucositis in Patients With Head and Neck Cancer Who Have Undergone Chemoradiation Therapy Condition: Mucositis Recurrent Squamous Cell Carcinoma of the Hypopharynx Date: 2012-08-02 Interventions: Other: placebo Given PO |
Terminated |
Study Name: Talactoferrin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer or Squamous Cell Head and Neck Cancer Condition: Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma Recurrent Metast Date: 2012-02-03 Interventions: Biological: talactoferrin Give |
Active, not recruiting |
Study Name: Phase 1b Food Based Modulation of Biomarkers in Human Tissues at High-Risk for Oral Cancer. Condition: Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma Salivary Gland S Date: 2011-10-27 Interventions: Other: placebo Receive lozenge |
Completed |
Study Name: Cetuximab and Everolimus in Treating Patients With Metastatic or Recurrent Colon Cancer or Head and Neck Cancer Condition: Recurrent Adenoid Cystic Carcinoma of the Oral Cavity Recurrent Basal Cell Carcinoma of the Date: 2011-10-20 Interventions: Drug: everolimus Given PO |
Withdrawn |
Study Name: Everolimus, Erlotinib Hydrochloride, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer Previously Treated With Radiation Therapy Condition: Recurrent Metastatic Squamous Neck Cancer With Occult Primary Recurrent Salivary Gland Cance Date: 2011-04-07 Interventions: Drug: everolimus Given PO |
Completed |
Study Name: TLR8 Agonist VTX-2337 and Cetuximab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Squamous Cell Cancer of Head and Neck Condition: Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma Recurrent Metast Date: 2011-03-21 Interventions: Drug: TLR8 agonist VTX-2337 Gi |
Active, not recruiting |
Study Name: Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell Cancer Condition: Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma Recurrent Metast Date: 2011-03-08 Interventions: Biological: cetuximab Given IV |
Not yet recruiting |
Study Name: Treatment of Malignant Sinonasal Tumours With Intensity-modulated Radiotherapy (IMRT) and Carbon Ion Boost (C12) Condition: Sinonasal Malignancies: Adenocarcinoma and Squamous Cell Carcinoma of the Paranasal Sinuses Date: 2010-10-12 Interventions: Radiation: carbon ion boost 8 fractions carbon ion (8 x 3 GyE C12) therapy followed by 25 fractions of I |
Completed |
Study Name: Erlotinib, Celecoxib and Reirradiation for Recurrent Head and Neck Cancer Condition: Cancer of the Pharynx Cancer of the Larynx Cancer of the N Date: 2009-09-01 Interventions: Drug: erlotinib + celecoxib In this phase I/II study, patients will be treated with daily erlotinib 150 |
Completed |
Study Name: Photon/Proton Radiation Therapy for Cancers of the Nasal Cavity and/or Paranasal Sinuses Condition: Cancers of Nasal Cavity Cancers of Paranasal Sinuses Date: 2008-11-24 Interventions: Other: Xerostomia questionnaire All of the tests, procedures and treatments may be considered standard o |